Latest Insider Transactions at Arrowhead Pharmaceuticals, Inc. (ARWR)
This section provides a real-time view of insider transactions for Arrowhead Pharmaceuticals, Inc. (ARWR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARROWHEAD PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARROWHEAD PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,586
-0.16%
|
$855,848
$68.59 P/Share
|
|
Dec 19
2025
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
10,000
-8.17%
|
$670,000
$67.74 P/Share
|
|
Dec 19
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,445
-0.12%
|
$900,815
$67.72 P/Share
|
|
Dec 19
2025
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
10,040
-7.87%
|
$672,680
$67.66 P/Share
|
|
Dec 19
2025
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
8,367
-4.44%
|
$560,589
$67.73 P/Share
|
|
Dec 17
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
85,000
-0.55%
|
$5,440,000
$64.97 P/Share
|
|
Dec 16
2025
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+15.21%
|
-
|
|
Dec 16
2025
|
Douglas S Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+14.47%
|
-
|
|
Dec 16
2025
|
Victoria Vakiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+14.59%
|
-
|
|
Dec 16
2025
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+5.97%
|
-
|
|
Dec 16
2025
|
Lu Hongbo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+12.45%
|
-
|
|
Dec 16
2025
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+9.26%
|
-
|
|
Dec 16
2025
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,819
+10.75%
|
-
|
|
Dec 16
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
54,298
-0.15%
|
$3,475,072
$64.05 P/Share
|
|
Dec 15
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
130,000
-1.06%
|
$8,970,000
$69.3 P/Share
|
|
Dec 12
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,000
+4.2%
|
-
|
|
Dec 05
2025
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
16,250
-12.36%
|
$991,250
$61.03 P/Share
|
|
Nov 28
2025
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
8,750
-11.29%
|
$490,000
$56.39 P/Share
|
|
Oct 01
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-8.62%
|
$700,000
$35.0 P/Share
|
|
Sep 12
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-6.07%
|
$450,000
$30.0 P/Share
|
|
Sep 02
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.72%
|
$375,000
$25.0 P/Share
|
|
Aug 15
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,389
-3.46%
|
$187,780
$20.0 P/Share
|
|
Aug 13
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
611
-0.22%
|
$12,220
$20.0 P/Share
|
|
Apr 11
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,800
-1.28%
|
$558,800
$11.49 P/Share
|
|
Apr 10
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-1.24%
|
$500,000
$10.87 P/Share
|
|
Apr 09
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,322
-0.33%
|
$403,220
$10.81 P/Share
|
|
Mar 13
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
51,425
-1.25%
|
$771,375
$15.07 P/Share
|
|
Mar 13
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
340,000
+7.63%
|
-
|
|
Mar 04
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
133,333
-3.41%
|
$2,266,661
$17.02 P/Share
|
|
Mar 04
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
133,333
+3.17%
|
$933,331
$7.75 P/Share
|
|
Mar 03
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
166,667
-4.09%
|
$3,000,006
$18.03 P/Share
|
|
Mar 03
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
166,667
+4.06%
|
$1,166,669
$7.75 P/Share
|
|
Feb 07
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,550
+0.25%
|
$191,000
$20.1 P/Share
|
|
Feb 06
2025
|
Douglas S Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,396
+50.0%
|
$767,920
$20.09 P/Share
|
|
Jan 23
2025
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
959
-2.61%
|
$20,139
$21.0 P/Share
|
|
Jan 07
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,000
-1.92%
|
$342,000
$19.7 P/Share
|
|
Jan 07
2025
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
8,000
-1.49%
|
$152,000
$19.69 P/Share
|
|
Jan 06
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,167
-2.75%
|
$516,173
$19.89 P/Share
|
|
Jan 06
2025
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
29,184
-2.62%
|
$554,496
$19.9 P/Share
|
|
Jan 06
2025
|
James C Hamilton Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
32,729
-5.51%
|
$621,851
$19.9 P/Share
|
|
Jan 04
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+16.65%
|
-
|
|
Jan 04
2025
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+15.05%
|
-
|
|
Jan 04
2025
|
James C Hamilton Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+24.7%
|
-
|
|
Jan 02
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,520
-0.31%
|
$218,880
$19.05 P/Share
|
|
Dec 27
2024
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
2,850
-7.2%
|
$57,000
$20.0 P/Share
|
|
Dec 23
2024
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,563
-0.33%
|
$238,697
$19.59 P/Share
|
|
Dec 18
2024
|
Lu Hongbo Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,733
+26.19%
|
$368,126
$22.99 P/Share
|
|
Dec 18
2024
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,733
+11.29%
|
$368,126
$22.99 P/Share
|
|
Dec 18
2024
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,733
+17.75%
|
$368,126
$22.99 P/Share
|
|
Dec 18
2024
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,733
+22.66%
|
$368,126
$22.99 P/Share
|